COVID19-associated new-onset movement disorders: a follow-up study

J Neurol. 2023 May;270(5):2409-2415. doi: 10.1007/s00415-023-11661-x. Epub 2023 Mar 21.

Abstract

Background: Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited.

Methods: Cases with new-onset COVID-19-associated movement disorders were identified by searching the literature. Authors were contacted for outcome data which were reviewed and analyzed.

Results: Movement disorders began 12.6 days on average after the initial onset of COVID-19. 92% of patients required hospital admission (mean duration 23 days). In a fraction of patients (6 of 27; 22%; 4 males/2 females, mean age 66.8 years) the movement disorder (ataxia, myoclonus, tremor, parkinsonism) was still present after a follow-up period of 7.5 ± 3 weeks. Severe COVID-19 in general and development of encephalopathy were risk factors, albeit not strong predictors, for the persistence.

Conclusions: The prognosis of new-onset COVID-19-associated movement disorder appears to be generally good. The majority recovered without residual symptoms within several weeks or months. Permanent cases may be due to unmasking of a previous subclinical movement disorder or due to vascular/demyelinating damage. Given the relatively low response rate of one third only and the heterogeneity of mechanisms firm conclusions on the (long-term) outome cannot, however, be drawn.

Keywords: COVID; Long covid; Movement disorder; Myoclonus ataxia; Outcome; Parkinsonism; Sars-CoV2.

MeSH terms

  • Aged
  • COVID-19* / complications
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Movement Disorders* / etiology
  • Risk Factors
  • Tremor / complications